Medistem Inc. announced today positive safety data from the first 5 patients enrolled in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy (RECOVER-ERC) trial. The clinical trial uses the company’s “Universal Donor” Endometrial Regenerative Cells (ERC) to treat Congestive Heart Failure (CHF).
According to the study design, after 5 patients enter the trial, they must be observed for a two month time period before additional patients are allowed to enter the study. Patient data was analyzed by the study’s independent Data Safety Monitoring Board (DSMB), which concluded that based on lack of adverse effects,
Medistem Inc. announced the appointment of Dr. Hugh S. Taylor to its Scientific Advisory Board. Dr. Taylor is the first scientist to identify the bone marrow origin of endometrial tissue, and performed independent experiments demonstrating that endometrial stem cells are capable of treating diabetes and Parkinson’s Disease in animal models.
Dr. Taylor is Professor of Obstetrics, Gynecology, and Reproductive Sciences; Section Chief, Reproductive Endocrinology and Infertility; Director, Yale Center for Endometrium and Endometriosis and Director of the Yale Center for Reproductive Biology.
“Dr. Taylor has literally defined the field of endometrial stem cells. His fundamental discovery of the bone marrow origin